Dapagliflozin modulates plasma lipidomic profile and urinary metabolite excretion in type 2 diabetes.

1 B); fasting plasma glucose showed a trend toward an improvement, although statistically not significant.

also in 53,322 other papers

However, when the two treatments were analyzed separately, the correlation between acylcarnitines and FFAs remained significant only in the HCT group, but was lost in the DAPA group, while the correlation between β-hydroxybutyrate and acylcarnitines was lost in both treatments but maintained a positive trend (Supplementary Figure S2).

also in 11,005 other papers